HOTH Hoth Therapeutics Inc
9,700
$1.19
$0.02
(1.71%)
| Watchers | 9,700 |
| 52-Wk Low | $0.99 |
| 52-Wk High | $4.30 |
| Market Cap | $5.72M |
| Volume | 11,244.00 |
| 52-Wk High | $4.30 |
| 52-Wk Low | $0.99 |
Hoth Therapeutics to Attend EF Hutton Annual Global Conference, May 15, 2024PR Newswire • 6 days ago
Hoth Therapeutics to Attend EF Hutton Annual Global Conference, May 15, 2024 Hoth Therapeutics to Attend EF Hutton Annual Global Conference, May 15, 2024 PR Newswire NEW YORK, May 1, 2024 NEW YORK...
Share to Feed
Hoth Therapeutics' Wholly Owned Subsidiary Merveille.ai, Advances AI-Driven Discovery for Obesity Treatment Hoth Therapeutics' Wholly Owned Subsidiary Merveille.ai, Advances AI-Driven Discovery for...
Hoth Therapeutics Announces Exercise of Warrants for $4.2 Million Gross Proceeds Hoth Therapeutics Announces Exercise of Warrants for $4.2 Million Gross Proceeds PR Newswire NEW YORK, March 27, 2024...
See the rest of the story here.
thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
Hoth Therapeutics Announces Positive Data In Completed Study of Alzheimer's Disease Pre-Clinical Treatment with HT-ALZ Hoth Therapeutics Announces Positive Data In Completed Study of Alzheimer's...
Hoth Therapeutics, Inc. (NASDAQ:HOTH Get Free Report) was the recipient of a large decline in short interest during the month of February. As of February 29th, there was short interest...
Hoth Therapeutics reveals preclinical findings on HT-ALZ, a potential Alzheimer's therapeutic targeting the Substance P/Neurokinin 1 Receptor pathway. HT-ALZ exhibits significant reductions in...
Hoth Therapeutics Retains Venable LLP to Expand Its Patent Portfolio Hoth Therapeutics Retains Venable LLP to Expand Its Patent Portfolio PR Newswire NEW YORK, Feb. 29, 2024 NEW YORK, Feb. 29, 2024...
Hoth Therapeutics Engages Altasciences to Perform Key Study for HT-KIT Cancer Fighting Therapeutic Hoth Therapeutics Engages Altasciences to Perform Key Study for HT-KIT Cancer Fighting Therapeutic...
Hoth Therapeutics to Attend BIO CEO and Investor Conference, February 26-27, 2024 Hoth Therapeutics to Attend BIO CEO and Investor Conference, February 26-27, 2024 PR Newswire NEW YORK, Feb. 13, 2024...